Federated Hermes’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Federated Hermes’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,214,972	Closed	-$38.6M	–	2230
2023 Q2	$38.6M	Sell	1,214,972 -710,000	-37%	-$21.8M	0.1%	252
2023 Q1	$47M	Sell	1,924,972 -942,479	-33%	-$27.7M	0.12%	218
2022 Q4	$90.4M	Sell	2,867,451 -445,882	-13%	-$12.6M	0.25%	82
2022 Q3	$93.6M	Buy	3,313,333 +200,000	+6%	+$5.96M	0.27%	79
2022 Q2	$82.3M	Hold	3,113,333	–	–	0.22%	108
2022 Q1	$109M	Hold	3,113,333	–	–	0.25%	104
2021 Q4	$101M	Hold	3,113,333	–	–	0.19%	151
2021 Q3	$91.8M	Buy	3,113,333 +1,163,333	+60%	+$32.7M	0.17%	162
2021 Q2	$50M	Hold	1,950,000	–	–	0.09%	283
2021 Q1	$26.8M	Buy	1,950,000 +998,300	+105%	+$14.6M	0.05%	424
2020 Q4	$15.8M	Buy	+951,700	New	+$12.4M	0.03%	530

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes's CERE Position: Q3 2023 in Review

Federated Hermes sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 1,214,972 shares — an estimated $38.6M sold.

Federated Hermes first reported a position in CERE in Q4 2020 and held it in 11 quarters. The position peaked at $109M in Q1 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

Federated Hermes reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 1,214,972 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $38.6M.
Federated Hermes first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Federated Hermes's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $109M in Q1 2022.
119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.